CN101563344B - Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors - Google Patents
Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors Download PDFInfo
- Publication number
- CN101563344B CN101563344B CN2007800472000A CN200780047200A CN101563344B CN 101563344 B CN101563344 B CN 101563344B CN 2007800472000 A CN2007800472000 A CN 2007800472000A CN 200780047200 A CN200780047200 A CN 200780047200A CN 101563344 B CN101563344 B CN 101563344B
- Authority
- CN
- China
- Prior art keywords
- disorder
- pain
- syndrome
- compound
- base
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 **(C(CC1)C2)C1CC2O* Chemical compound **(C(CC1)C2)C1CC2O* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
This invention relates to novel chromen-2-one derivatives of Formula (I) useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compoundsin a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.
Description
Technical field
The present invention relates to the chromen-2-one derivatives of the novelty of useful as monoamines neurotransmitter re-uptake.
In others, the present invention relates to the purposes of these compounds in methods of treatment and the pharmaceutical composition that comprises The compounds of this invention.
Background technology
Serotonin selectivity reuptake inhibitor (SSRI) at present at several CNS obstacles, comprise in the treatment of dysthymia disorders and Phobias effectiveness be provided.SSRI usually by psychopathist and primary care physicians think effectively, well-tolerated and be easy to administration.Yet they are relevant with many not desired characteristics.
Therefore, re-uptake activity, for example serotonin reuptake transporter and norepinephrine and the active ratio of dopamine reuptake at monoamine neurotransmitter serotonin, Dopamine HCL and norepinephrine still have tight demand to the compound with best pharmacological characteristic.
WO 2006/035034 and WO 2007/093604 (belonging to NeuroSearch A/S) disclose chromen-2-one derivatives and they purposes as monoamine neurotransmitter re-uptake.
Summary of the invention
An object of the present invention is, the compound that shows as the active novelty of monoamine neurotransmitter re-uptake is provided.
In aspect its first, the invention provides formula I compound:
Any mixture of its any stereoisomer or its steric isomer, or its pharmacy acceptable salt,
R wherein
1With Q as giving a definition.
In aspect its second, the invention provides pharmaceutical composition, it comprises the The compounds of this invention for the treatment of significant quantity, any mixture of its any stereoisomer or its steric isomer, or its pharmacy acceptable salt, and at least a pharmaceutically acceptable carrier, vehicle or thinner.
In aspect further one, any mixture or its pharmacy acceptable salt that the invention provides The compounds of this invention, its any stereoisomer or its steric isomer is used to prepare treatment, prevent or alleviate Mammals, comprises the purposes of the pharmaceutical composition of Human diseases or obstacle or illness that described disease, obstacle or illness are replied for the inhibition of monoamine neurotransmitter re-uptake in the central nervous system.
In further aspect one, the present invention relates to be used for the treatment of, prevent or alleviate the method for disease, obstacle or the illness of the animal body of the work that comprises the people, described disease, obstacle or illness are replied for the inhibition of monoamine neurotransmitter re-uptake in the central nervous system, and this method comprises any mixture or its pharmacy acceptable salt of The compounds of this invention, its any stereoisomer or its steric isomer of the animal body treatment significant quantity of this work that these needs are arranged.
From following detailed and embodiment, other purpose of the present invention to those skilled in the art will be apparent.
Of the present invention open in detail
Chromen-2-one derivatives
In aspect its first, the invention provides formula I compound:
Any mixture of its any stereoisomer or its steric isomer,
Or its pharmacy acceptable salt,
Wherein
Q represents chromene-2-ketone group;
This chromen-2-one base is replaced by a heteroaryl;
This heteroaryl randomly is independently selected from following substituting group and replaces by one or more:
Halogen, trifluoromethyl, trifluoromethoxy, cyano group, amino, nitro, hydroxyl, alkoxyl group, cycloalkyloxy, methylene-dioxy, ethylenedioxy, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl and alkynyl;
And this chromen-2-one base randomly further is independently selected from following substituting group and replaces by one or more:
Halogen, trifluoromethyl, trifluoromethoxy, cyano group, amino, nitro, hydroxyl, alkoxyl group, cycloalkyloxy, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl and alkynyl;
R
1Represent hydrogen or alkyl;
This alkyl randomly is independently selected from following substituting group and replaces by one or more:
Halogen, trifluoromethyl, trifluoromethoxy, cyano group, amino, nitro, hydroxyl, alkoxyl group, cycloalkyloxy, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl and alkynyl.
In an embodiment of formula I compound, R
1Represent hydrogen or alkyl.In a specific embodiments, R
1Represent hydrogen.
In another embodiment of formula I compound, chromen-2-one-7-base that the Q representative replaces.
In another embodiment of formula I compound, Q represents 3-(the optional heteroaryl that replaces)-chromen-2-one base.
In another embodiment of formula I compound, the Q representative is by the chromen-2-one-7-base of furyl or benzofuryl replacement.In a specific embodiments, the Q representative is by the chromen-2-one-7-base of furyl, for example furans-2-base or furans-3-base replacement.In another embodiment, the Q representative is by the chromen-2-one-7-base of benzofuryl, for example cumarone-2-base replacement.
In a specific embodiments, compound of the present invention is
Outward-and 7-[(1S, 3S, 5R)-(8-aza-bicyclo [3.2.1] oct-3-yl) oxygen base]-3-furans-2-base-chromen-2-one;
Outward-and 7-[(1S, 3S, 5R)-(8-aza-bicyclo [3.2.1] oct-3-yl) oxygen base]-3-furans-3-base-chromen-2-one;
Outward-and 7-[(1S, 3S, 5R)-(8-aza-bicyclo [3.2.1] oct-3-yl) oxygen base]-3-cumarone-2-base-chromen-2-one;
Or its pharmacy acceptable salt.
The arbitrary combination of two or more a plurality of above-mentioned embodiments is regarded as within the scope of the present invention.
The substituting group definition
In the context of the invention, halogen is represented fluorine, chlorine, bromine or iodine.
In the context of the invention, alkyl is represented unit price hydrocarbon chain saturated, straight or branched.This hydrocarbon chain preferably contains one to six carbon atom (C
1-6-alkyl), comprises amyl group, isopentyl, neo-pentyl, tert-pentyl, hexyl and isohexyl.In a preferred embodiment, alkyl is represented C
1-4-alkyl comprises butyl, isobutyl-, sec-butyl and the tertiary butyl.In another embodiment preferred of the present invention, alkyl is represented C
1-3-alkyl, it can be methyl, ethyl, propyl group or sec.-propyl especially.
In the context of the invention, alkenyl represents to contain the carbochain of one or more pair key, comprises two-alkene, three-alkene and many-alkene.In a preferred embodiment, alkenyl of the present invention contains two to six carbon atom (C
2-6-alkenyl), it comprises at least one two key.In a most preferred embodiment, alkenyl of the present invention is a vinyl; 1-propenyl or 2-propenyl; 1-butylene base, crotyl or 3-butenyl, or 1,3-butadiene base: 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl or 5-hexenyl, or 1, the 3-hexadienyl, or 1,3,5-hexatriene base.
In the context of the invention, alkynyl represents to contain one or more triple-linked carbochain, comprises two-alkynes, three-alkynes and many-alkynes.In a preferred embodiment, alkynyl of the present invention contains two to six carbon atom (C
2-6-alkynyl), comprise at least one triple bond.In its most preferred embodiment, alkynyl of the present invention is an ethynyl; 1-proyl or 2-propynyl: ethyl acetylene base, 2-butyne base or 3-butynyl, or 1,3-diacetylene base; 1-pentynyl, valerylene base, 3-pentynyl, 4-pentynyl, or 1,3-pentadiine base; 1-hexin base, 2-hexin base, 3-hexin base, 4-hexin base or 5-hexin base, or 1,3-hexadiyne base, or 1,3, oneself three alkynyls of 5-.
In the context of the invention, cycloalkyl is represented cyclic alkyl, preferably contains three to seven carbon atom (C
3-7-cycloalkyl), comprises cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and suberyl.
Alkoxyl group is the O-alkyl, and alkyl wherein as defined above.
Cycloalkyloxy is the O-cycloalkyl, and cycloalkyl wherein as defined above.
Cycloalkylalkyl means aforesaid cycloalkyl and aforesaid alkyl, means for example cyclopropyl methyl.
Amino is NH
2Or NH-alkyl or N-(alkyl)
2, wherein alkyl as defined above.
In the context of the invention, heteroaryl is represented aromatic monocyclic or bicyclic heterocyclic group, and it has one or more heteroatomss in its ring structure.Preferred heteroatoms comprises nitrogen (N), oxygen (O), and sulphur (S).
Preferred bicyclic heteroaryl of the present invention comprises aromatics 5-and 6-unit heterocycle monocyclic groups, comprises, such as but not limited to ， oxazolyl ， isoxazolyl, thiazolyl, isothiazolyl, tetrazyl, 1,2,4-oxadiazole base, 1,2,5-oxadiazole base, 1,3,4-oxadiazole base, triazolyl, 1,2,4-thiadiazolyl group, 1,2,5-thiadiazolyl group, imidazolyl, pyrryl, pyrazolyl, furyl, thienyl, pyridyl, pyrimidyl, or pyridazinyl.
Preferred bicyclic heteroaryl of the present invention comprises, such as but not limited to, indolizine base, indyl, pseudoindoyl, indazolyl, benzofuryl, benzo [b] thienyl, benzimidazolyl-, benzoxazolyl, Ben Bing oxadiazole base, benzothiazolyl, benzo [d] isothiazolyl, purine radicals, quinolyl, isoquinolyl, the cinnolines base, phthalazinyl, quinazolyl ， quinoxalinyl, 1,8-naphthyridinyl, pteridyl, and indenyl.
Pharmacy acceptable salt
The compounds of this invention can any suitable plan administration form provide.The form that is fit to comprises that the pharmacy (being physiology) of The compounds of this invention goes up acceptable salt and prodrug (predrug) or prodrug (prodrug) form.
The example of pharmaceutically acceptable addition salt includes but not limited to: non-toxic inorganic and organic acid addition salt, for example hydrochloride, hydrobromate, nitrate, perchlorate, phosphoric acid salt, vitriol, formate, acetate, aconate, ascorbate salt, benzene sulfonate, benzoate, cinnamate, Citrate trianion, embonate, enanthate, fumarate, glutaminate, oxyacetate, lactic acid salt, maleate, malonate, mandelate, mesylate, the naphthalene-2-sulfonic acid salt derivative, phthalate, salicylate, sorbate, stearate, succinate, tartrate, right-tosylate etc.Such salt can form by the method for knowing in this area and describing.
Other acids is oxalic acid for example, and it may not be considered to be pharmaceutically acceptable, but can be used in the preparation of salt, and described salt can be used as intermediate product in obtaining The compounds of this invention and pharmaceutically-acceptable acid addition thereof.
The example of the pharmaceutically acceptable cationic salts of The compounds of this invention includes but not limited to: contain the sodium salt of the The compounds of this invention of anionic group, sylvite, calcium salt, magnesium salts, zinc salt, aluminium salt, lithium salts, choline salt, lysine salt and ammonium salt etc.Such cationic salts can form by the method for knowing in this area and describing.
In the context of the invention, " salt " of nitrogenous compound also is considered to pharmacy acceptable salt.Preferably " salt " comprises alkyl-salt, cycloalkyl-salt and cycloalkylalkyl-salt.
The example of the prodrug of The compounds of this invention or prodrug form comprises the example of material appropriate drug precursor of the present invention, is included in adorned compound on one or more reactions of parent compound or the deriveding group.Making us compound of interest especially is adorned compound on carboxyl, hydroxyl or amino.The appropriate derivative example is ester or acid amides.
The compounds of this invention can solvable or insoluble form provide with pharmaceutically acceptable solvent such as water, ethanol etc.Soluble form can also comprise hydrated form, for example monohydrate, dihydrate, semihydrate, trihydrate, tetrahydrate etc.Usually, with regard to the object of the invention, think that soluble form is equal to insoluble form.
Steric isomer
Those skilled in the art will recognize that the stereoisomeric forms in any ratio that The compounds of this invention can be different exists, and comprises enantiomer, diastereomer and cis-trans isomer.
For example, group-O-Q of formula I can be specifically with respect to the outer or interior configuration of azabicyclo.
The present invention includes all these steric isomers and any mixture thereof, comprise racemic mixture.
Racemic form can split into optical antipode with known method and technology.The method of a kind of enantiomer separation compound (comprising the enantiomorph intermediate) is, is under the situation of chiral acid at described compound, uses optically active amines, and by discharge the dissolved salt of diastereomer with acid treatment.The another kind of method that racemic compound is split into optical antipode is based on the chromatogram on the optical activity matrix.Therefore, for example by fractional crystallization D-or L-(tartrate, mandelate or camsilate) salt, racemic compound of the present invention can be split into their optical antipode.
The compounds of this invention can also split by the following method: make The compounds of this invention and optical activity activatory carboxylic acid, such as forming diastereomeric acid amides, perhaps make the reaction of compound of the present invention and optically active chloro-formic ester or analogue form diastereomeric carbamate by (+) or (-) phenylalanine, (+) or (-) phenylglycocoll, (+) or (-) dextrocamphoric acid deutero-carboxylic acid reaction.
Other method that is used to split optical isomer is well known in the art.Such method comprises Jaques J, Collet A ， ﹠amp; Wilen S exists "
Enantiomers.Racemates, And Resolutions", those methods described in the John Wiley and Sons, New York (1981).
Optically active compound can also be from the optical activity feedstock production.
The compound of mark
The compounds of this invention can its mark or the use of unlabelled form.In the context of the invention, this tagged compound has one or more atom, and described atom is had to be different from the atomic mass usually found at occurring in nature or the atomic mass of total mass number or the atom of total mass number and to replace.Described mark can make the easy detection by quantitative of this compound.
The compound of mark of the present invention can be used as diagnostic tool, radiotracer or the monitoring agent in the various diagnostic methods, and can be used for the imaging of body inner recipient.
The compound of mark of the present invention preferably comprises at least a radionuclide and serves as a mark.The radionuclide of emission positron is the use material standed for.In the context of the invention, radionuclide is preferably selected from
2H (deuterium),
3H (tritium),
11C,
13C,
14C,
131I,
125I,
123I and
18F.
The physical method that is used to detect the compound of mark of the present invention can be selected from positron emission tomography art (PET), single photon tomography computer tomography (SPECT), nuclear magnetic resonance spectroscopy method (MRS), nuclear magnetic resonance (MRI) and the axial x-ray tomography imaging of area of computer aided art (CAT) or their combination.
The preparation method
Compound of the present invention can be by being used for the ordinary method of chemosynthesis, for example described in an embodiment method preparation.The raw material that is used for the described method of the application is known, perhaps can be easily by ordinary method by the chemical production that is obtained commercially.
Can also a kind of compound of the present invention be changed into another kind of compound of the present invention with ordinary method.
The end product of reaction described herein can pass through routine techniques, for example separates by extraction, crystallization, distillation, chromatogram etc.
Biological activity
Can test The compounds of this invention and suppress the ability of monoamine Dopamine HCL, norepinephrine and serotonin reuptake transporter in the synaptosome, as described in the WO97/30997 (NeuroSearch A/S).Based on observed equilibrium activity in these tests, consideration is used for the treatment of The compounds of this invention, prevent or alleviates Mammals, comprises people's disease or obstacle or illness, and described disease, obstacle or illness are replied the inhibition of the monoamine neurotransmitter re-uptake in the central nervous system.
In a specific embodiment, consider compound of the present invention is used for the treatment of, the prevention or alleviate: affective disorder, depressed, the atypia depression, be secondary to the depression of pain, major depressive disorder, dysthymic disorder, bipolar disorder, I type bipolar disorder, II type bipolar disorder, cyclothymic disorder, the affective disorder that causes by the general medicine illness, material inductive affective disorder, pseudodementia, Ganser's syndrome, obsessional idea and behavior disorder, Phobias, the Phobias of no agoraphobia, the Phobias that agoraphobia is arranged, the agoraphobia of no Phobias medical history, panic attack, memory impairment, the loss of memory, the distractibility hyperkinetic syndrome, fat, anxiety, generalized-anxiety disorder, eating disorder, Parkinson's disease, Parkinson, dull-witted, old and feeble dementia, senile dementia, Alzheimer, mongolism, the dull-witted complex of acquired immune deficiency syndrome (AIDS), aging memory machine dysfunction, specific phobia disease, social phobia, social anxiety disorder, nervous obstacle after the wound, acute stress disorder, the chronic stress obstacle, drug habit, drug abuse, the drug abuse tendency, cocaine abuse, the nicotine abuse, tobacco abuse, alcohol addiction, alcoholism, the kleptomania, stop the Withrawal symptom that the use addictive substance causes, pain, chronic pain, inflammatory pain, neuropathic pain, diabetes nerve pain, migraine, tension-type headache, chronic tension-type headache, the pain relevant with depression, fibromyalgia, sacroiliitis, osteoarthritis, rheumatoid arthritis, back pain, pain caused by cancer, intestines easily swash property pain, irritable bowel syndrome, post-operative pain, mastectomy postoperative pain syndrome (PMPS), pain after the apoplexy, drug-induced neuropathy, diabetic neuropathy, sympathetic nerve maintenance pain, trigeminal neuralgia, toothache, muscular fascia pain, phantom limb pain, exessive appetite, premenstrual syndrome, premenstrual dysphoric disorder, the evening luteal phase syndrome, posttraumatic syndrome, chronic fatigue syndrome, the persistence persistent vegetative state, the urinary incontinence, the pressure incontinence, urge incontinence, the incontinence at night, sexual dysfunction, premature ejaculation, it is difficult to erect, erective dysfunction, too early female orgasm, restless legs syndrome, Periodic limb movement disorder, eating disorder, anorexia nervosa, somnopathy, PDD, autism, the A Sibogeer obstacle, the special obstacle of thunder, childhood disintegrative disorder, the learning capacity forfeiture, motor skill disorder, mutism, trichotillomania, narcolepsy, the apoplexy retarded depression, apoplexy inductive brain injury, apoplexy inductive neuronal damage, Ji Ledelatulei syndrome, tinnitus, tic disorder, body deformability mental disorder, disabled after oppositional defiant disorder or the apoplexy.In a preferred embodiment, consider described compound is used for the treatment of, prevents or alleviate depression.
The suitable dosage range of expection active pharmaceutical ingredient (API) is about 0.1 to about 1000mg API/ day at present, more preferably about 10 to about 500mg API/ days, most preferably about 30 to about 100mg API/ days, but depend on the indication, patient of definite administering mode, its form of medication, consideration and particularly related patient's body weight, and further, attending doctor or animal doctor's preference and experience.
Preferred The compounds of this invention shows the biological activity of sub-micro mole and micro-molar range, promptly less than 1 to about 100 μ M.
Pharmaceutical composition
In one aspect of the method, the invention provides the novel pharmaceutical combination thing, it comprises the The compounds of this invention for the treatment of significant quantity.
Although the form administration that the The compounds of this invention that is used for the treatment of can starting compound, but preferably with activeconstituents, randomly with the form of physiologically acceptable salt, introducing with one or more assistant agents, vehicle, carrier, buffer reagent, thinner and/or other conventional excipient substance becomes pharmaceutical composition.
In preferred embodiments, the invention provides pharmaceutical composition, it comprises The compounds of this invention or its pharmacy acceptable salt or derivative and one or more pharmaceutically acceptable carriers and therapeutic and/or preventative composition randomly known in the art with other and that use and mixes.This carrier must be " acceptable ", promptly with preparation in other composition compatible and can be harmful to its recipient.
Pharmaceutical composition of the present invention can be those pharmaceutical compositions that are suitable for oral, rectum, segmental bronchus, nose, lung, part (comprising in the cheek and the hypogloeeis), transdermal, vagina or parenteral (comprise in skin, subcutaneous, intramuscular, intraperitoneal, intravenously, intra-arterial, the brain, intraocular injection or infusion) administration, or those are adapted to pass through the forms that suck or be blown into administration, comprise powder and liquid aerosol drug delivery or the pharmaceutical composition by the slow-released system administration.The example of suitable slow-released system comprises the semi-permeable matrix of the solid hydrophobic polymkeric substance that contains The compounds of this invention, and this matrix can be the formed article form, for example film or micro-capsule.
Therefore compound of the present invention can be made the form of pharmaceutical composition and unitary dose thereof with assistant agent, carrier or the thinner of routine.Such form comprises solid, and the especially form and the liquid of tablet, filled capsules, powder and pill, especially the capsule of the aqueous solution or non-aqueous solution, suspension, emulsion, elixir and the above-mentioned form of filling, the suppository that all these forms all is used for is oral, be used for rectal administration and be used for parenteral sterile injectable solution.Such pharmaceutical composition and unit dosage form thereof can comprise conventional ratio conventional ingredient, contain or do not contain other active compound or composition, and such unit dosage form can contain the activeconstituents of any suitable effective amount suitable with expection application dose scope every day.
The compounds of this invention can various oral and parenteral dosage form administrations.For a person skilled in the art, it is evident that following formulation can comprise The compounds of this invention or the The compounds of this invention pharmacy acceptable salt as activeconstituents.
For from the The compounds of this invention pharmaceutical compositions, pharmaceutically acceptable carrier can be solid or liquid.The preparation of solid form comprises powder, tablet, pill, capsule, cachet, suppository and dispersible granules agent.Solid carrier can be one or more materials that can also be used as thinner, seasonings, solubilizing agent, lubricant, suspension agent, tackiness agent, sanitas, tablet disintegrant or coating material.
In powder agent, carrier is a fine-grained solids, and it mixes with the active ingredient of segmentation.
In tablet, activeconstituents mixes in the proper ratio with the carrier with necessary binding capacity and is compressed into required shape and size.
Powder agent and tablet preferably contain 5% or 10% to about 70% active compound.Suitable carriers is magnesiumcarbonate, Magnesium Stearate, talcum powder, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth gum, methylcellulose gum, Xylo-Mucine, low melt wax, theobroma oil etc.Active compound and formulation as the coating material of carrier desired to comprise in term " preparation ", and described coating material provides capsule, wherein contains or carrier-free activeconstituents suppressed by vector surrounds, and carrier combines with active compound thus.Similarly, also comprise cachet and lozenge.Tablet, powder agent, capsule, pill, cachet and lozenge can be as the solid forms that is suitable for oral administration.
In order to prepare suppository, at first with low-melting wax, as the mixture melt of glycerin fatty acid ester or theobroma oil, and activeconstituents is evenly dispersed in wherein by stirring.In the suitable big or small mould of the uniform mixture impouring that will melt then, make its cooling and curing thus.
The composition that is suitable for vagina administration can vaginal suppository, the form of tampon, ointment, gelifying agent, paste, foam or sprays exists, and also contains suitable carriers known in the art except that containing activeconstituents.
Liquid preparation comprises solution, suspension and emulsion, for example, and the aqueous solution or water-propylene glycol solution.For example, the parenteral injection liquid preparation can be mixed with the solution of moisture polyoxyethylene glycol.
Therefore, The compounds of this invention can be mixed with and be used for administered parenterally (for example injection, as inject or continuous infusion) preparation, and can provide with the unit dosage form of ampoule, pre-filled syringe, small volume transfusion or with multi-dose container with the sanitas that adds.Said composition can be taked the form of suspension, solution or the emulsion of oiliness or aqueous carrier, and can contain the preparation composition, as suspension agent, stablizer and/or dispersion agent.In addition, activeconstituents can be a powder type, and the aseptic separation by sterile solid or obtain by the solution freeze-drying is used for before use preparing with suitable carriers such as aseptic, pyrogen-free water.
The aqueous solution that is suitable for orally using can prepare by solubilization of active ingredient is also added suitable tinting material, seasonings, stablizer and thickening material as required in water.
The aqeous suspension that is suitable for orally using can by will segment active ingredient be dispersed in contain viscous substance, as natural or synthetic is gummy, prepare in the water of resin, methylcellulose gum, Xylo-Mucine or other known suspension agent.
Also comprise the solid form preparation of desiring before facing usefulness, to be converted into the liquid form preparation that is used for oral administration.Such liquid form comprises solution, suspension and emulsion.Except that active ingredient, such preparation can comprise tinting material, seasonings, stablizer, buffer reagent, artificial and natural sweeting agent, dispersion agent, thickening material, solubilizing agent etc.
In order to locally apply to epidermis, The compounds of this invention can be mixed with ointment, creme, or lotion, or transdermal patch.For example, ointment and creme can add suitable thickening and/or jelling agent is formulated with water-based or oleaginous base.Lotion can be formulated with water-based or oleaginous base, and also contain one or more emulsifying agents, stablizer, dispersion agent, suspension agent, thickening material or tinting material usually.
Be suitable for that topical drug delivery composition is included in flavoured base in the oral cavity, be generally the lozenge that comprises activeconstituents in sucrose and kordofan gum or the tragacanth gum; The pastille (pastilles) that comprises activeconstituents at inert base, as gelatin and glycerine or sucrose and kordofan gum; And the mouth wash shua that in suitable liquid vehicle, comprises activeconstituents.
Solution or suspension for example can be applied directly to nasal cavity with dropper, suction pipe or atomizer with ordinary method.Said composition can single dose or the form of multiple doses provide.
Respiratory tract administration also can be realized by aerosol, wherein activeconstituents provides in pressurized package with suitable propelling agent, suitable propelling agent comprises chlorofluorocarbon (CFC) for example Refrigerant 12, trichlorofluoromethane or dichloro tetrafluoro ethane, carbonic acid gas or other suitable gas.Aerosol also can suitably contain tensio-active agent such as Yelkin TTS.The dosage of medicine can be by being equipped with metering valve control.
Perhaps, activeconstituents can provide by dry powder form, for example the powdered mixture of compound in suitable powder matrix such as lactose, starch, starch derivative such as Vltra tears and polyvinylpyrrolidone (PVP).Aptly, powder carrier will form gel at nasal cavity.Powder composition can present by unit dosage form, for example with capsule or cartridge case (as the capsule or the cartridge case of gelatin) form, or can be by the sucker Blister Package form of administration therefrom with powder.
Comprise intranasal compositions at the composition of desiring to be used for respiratory tract administration, compound has little particle diameter usually, for example is 5 microns or the littler order of magnitude.Such particle diameter can be by methods known in the art, for example obtain by micronization.
When needing, can use the composition that is fit to provide the activeconstituents slowly-releasing.
Pharmaceutical preparation is preferably unit dosage form.In this class form, preparation is subdivided into the unitary dose that contains an amount of active ingredient.Unit dosage form can be the preparation of packing, and this packing contains the preparation of discrete amount, as tablet, the capsule of packing, and the powder in bottle or the ampoule.In addition, unit dosage form can be capsule, tablet, cachet or a lozenge itself, maybe can be the packaged form that is fit to any of these formulation of quantity.
The tablet or the capsule that are used for oral administration are preferred compositions with the liquid and the continuous infusion liquid that are used for intravenously administrable.
Can be in latest edition about the more detailed data of preparation and medicine-feeding technology
Remington ' s Pharmaceutical Sciences(Maack PublishingCo., Easton find on PA).
The treatment effective dose refers to the amount of activeconstituents, and it can improve symptom or symptom.Treatment effectiveness and toxicity, for example ED
50And LD
50Can in cell culture or laboratory animal, be measured by standard pharmacology program.But the dosage between result of treatment and the toxic action is than being therapeutic index and passing ratio LD
50/ ED
50Expression.Preferably show the pharmaceutical composition of big therapeutic index.
The dosage that gives certainly must be at age, body weight and the illness of the individuality of being treated, and route of administration, dosage form and dosage regimen, and the result of expectation and adjusting carefully, and definite dosage should be determined by the doctor certainly.
Actual dosage depends on the character and the severity of the disease for the treatment of, and within doctor's determination range, can be according to the present invention particular case the reaction of dosage is changed, to produce required result of treatment.Yet expection at present contains from about 0.1 to about 500mg, preferably from about 1 to about 100mg, more preferably the pharmaceutical composition from about activeconstituents of 1 to about 10mg/single dosage is suitable for therapeutic treatment.
Activeconstituents can every day one or several doses give.In some cases, can obtain gratifying result with the dosage that is low to moderate 0.1 μ g/ kilogram (intravenously) and 1 μ g/ kilogram (oral).Think that at present the upper limit of dosage range is about 10mg/ kilogram (intravenously) and 100mg/ kilogram (oral).Preferable range is from about 0.1 μ g/ kilogram to about 10mg/ kilogram/day (intravenously), and from about 1 μ g/ kilogram to about 100mg/ kilogram/day (oral).
Methods of treatment
In one aspect of the method, the invention provides treatment, prevent or alleviate the disease that animal body alive comprises the people, the method of obstacle or illness, this disease wherein, obstacle or illness are replied for the inhibition of monoamine neurotransmitter re-uptake in the central nervous system, and this method comprise the work that these needs are arranged animal body, comprise the The compounds of this invention of human significant quantity.
Expection at present, suitable dosage range is that every day 0.1 is to 1000mg, every day 10 is to 500mg, and particularly every day 30-100mg, depend on definite administering mode usually, form of medication, administration at indication, related patient and related patient's body weight, and further, doctor or animal doctor's preference and experience.
Embodiment
Further specify the present invention with reference to the following example, but these embodiment limit the desired scope of the invention unintentionally by any way.
Preparation embodiment
Under nitrogen and in anhydrous solvent, the institute that comprises airsensitive reagent or intermediate responds.With the siccative of sal epsom as post-processing operation, vapourisation under reduced pressure solvent.
Embodiment 1
In-phenylformic acid 8-methyl-8-aza-bicyclo [3.2.1] oct-3-yl ester
Under＜30 ℃, in 30min with Benzoyl chloride (84.3g, 600mmol) add tropine (70.6g, 500mmol), potassium tert.-butoxide (67.3g, 600mmol) and the mixture of THF (500ml).At stirring at room mixture 2h.Add entry (1L), use diethyl ether (2 * 500ml) extractions subsequently.(2 * 200ml) washing organic phases 2 times are used saturated sodium-chloride water solution (200ml) washing to water subsequently.Dry ether phase is added in ethanol (170ml, 3M) hydrochloric acid in.The hydrochloride of filtering-depositing washs with diethyl ether.By adding excess of ammonia water, obtain free alkali, use the mixture extraction of ethyl acetate and diethyl ether subsequently.Output 66.8g (54%).
In-phenylformic acid 8-aza-bicyclo [3.2.1] oct-3-yl ester
With 2,2,2 tri chloroethyl chloroformat (75.0ml, 544mmol) dropwise add in-(66.8g is 272mmol) and in the mixture of exsiccant toluene (500ml) for phenylformic acid 8-methyl-8-aza-bicyclo [3.2.1] oct-3-yl ester.Mixture at stirring at room 1h, is stirred 15h at 100 ℃ subsequently.Add entry (250ml), stir 1h subsequently.Separate phase, water (2 * 200ml) washing organic phases 2 times.The mixture of dry intermediate 3-benzoyloxy-8-aza-bicyclo [3.2.1] octane-8-formic acid trichloromethyl ester, and evaporation.Add acetate (350ml), with after 3 hour time period add zinc (53.4g, 817mmol).Add entry (100ml), ice-cooled by adding, by adding strong aqua (approximately 400ml) alkalization, with methylene dichloride (2 * 300ml) extraction mixtures.Output 44.5g (61%).
In-3-benzoyloxy-8-aza-bicyclo [3.2.1] octane-8-formic acid tertiary butyl ester
At room temperature, to be dissolved in di-t-butyl-two carbonic ether (39.9g among the THF (100ml) through 0.5h, 183mmol) add interior-phenylformic acid 8-aza-bicyclo [3.2.1] oct-3-yl ester (44.5g that stirs, 166.4mmol), triethylamine (67.4g, 666mmol) and in the mixture of THF (250ml), stir 1h then.Add entry (1L), with diethyl ether (2 * 300ml) extraction mixtures.Water (ether of 2 * 200ml) washing collections 2 times mutually, dry and evaporation.Output 60.1g (100%).
In-3-hydroxyl-8-aza-bicyclo [3.2.1] octane-8-formic acid tertiary butyl ester
In at room temperature stirring-3-benzoyloxy-8-aza-bicyclo [3.2.1] octane-8-formic acid tertiary butyl ester (55.0g, 166mmol), potassium hydroxide (11.2g 199mmol) and ethanol (99%, mixture 400ml) 3 days.By filtering separation potassium benzoate, evaporated filtrate.Add diethyl ether (200ml), the remaining potassium benzoate of filtering separation, evaporated filtrate.Use the sherwood oil grinding product.Output 30.0g (80%).Fusing point 139.5-140.8 ℃.
Outward-7-(8-tertbutyloxycarbonyl-8-aza-bicyclo [3.2.1] oct-3-yl oxygen base)-chromene
-2-ketone
(7.5g 28.6mmol) is dissolved in diox (70ml), is cooled to 8 ℃ with triphenylphosphine.(5.0g 28.6mmol) is added in mixture below 15 ℃, stirs subsequently 15 minutes with diethyl azepine dicarboxylic acid esters.With interior-3-hydroxyl-8-aza-bicyclo [3.2.1] octane-8-formic acid tertiary butyl ester (5.0g, 22.0mmol) and umbelliferone (4.3g 26.4mmol) adds mixture.Because thermopositive reaction, temperature raises.At stirring at room mixture 15h.Add entry (200ml), use diethyl ether (2 * 100ml) extractions subsequently.Drying composite and evaporation.In the enterprising circumstances in which people get things ready for a trip spectrum of silica gel, use methylene dichloride and 5% methyl alcohol as solvent.Crude product is dissolved in diethyl ether (200ml), with aqueous sodium hydroxide solution (3 * 200ml, 1M) washing.Desciccate and evaporation.Output 5.32g (65%).
Outward-and 7-[(1S, 3S, 5R)-(8-tert-butoxycarbonyl-8-aza-bicyclo [3.2.1] suffering
-3-yl) oxygen base]-3-bromo-chromen-2-one
With bromine (1.38ml, 27.0mmol) add outer-7-(8-tert-butoxycarbonyl-8-aza-bicyclo [3.2.1] oct-3-yl oxygen)-chromen-2-one (7.8g, 21.0mmol), acetic acid (150ml) and sodium-acetate (5.2g, mixture 63.0mmol).At stirring at room mixture 90min.Add entry (100ml).Filtering-depositing, water (10ml), methyl alcohol (5ml) and diethyl ether (20ml) washing.Output 7.5g (79%).
Method A
Outward-and 7-[(1S, 3S, 5R)-(8-aza-bicyclo [3.2.1] oct-3-yl) oxygen base]-the 3-furan
Mutter-2-base-chromen-2-one hydrochloride
Stir outer-7-[(1S, 3S, 5R)-(8-tert-butoxycarbonyl-8-aza-bicyclo [3.2.1] oct-3-yl) oxygen base]-3-bromo-chromen-2-one (2.0g, 4.0mmol), 2-furans boric acid (0.89g, 8.0mmol), salt of wormwood (1.66g, 12.0mmol), 1, the mixture of 2-glycol dimethyl ether (20ml) and water (10ml), perfusion argon 10min.Add Palladacycle (94mg, 0.1mmol) and Pd (PPh
3)
4(115mg 0.1mmol), refluxes then and stirs 2h.Make mixture be cooled to room temperature.Add entry (25ml), the solid of filtering-depositing.The acetum of stir solids and hydrogenchloride (20ml, mixture 3h 1M).By adding ammoniacal liquor, make the mixture alkalize.Be settled out product.In the enterprising circumstances in which people get things ready for a trip spectrum of silica gel, as solvent, produce pure free alkali with methylene dichloride, 10% methyl alcohol and 1% ammoniacal liquor.(5ml, 1M) the middle stirring changes into corresponding salt with compound by the acetum at hydrogenchloride.Output 150mg (12%).[M+H]+LC-ESI-HRMS demonstrate 338.1389Da.Calculated value 338.139234Da, deviation-1ppm.
Outward-and 7-[(1S, 3S, 5R)-(8-aza-bicyclo [3.2.1] oct-3-yl) oxygen base]-the 3-furan
Mutter-3-base-chromen-2-one hydrochloride
According to method A from outside-7-[(1S, 3S, 5R)-(8-tert-butoxycarbonyl-8-aza-bicyclo [3.2.1] oct-3-yl) oxygen base]-preparation of 3-bromo-chromen-2-one and 3-furans boric acid.[M+H]+LC-ESI-HRMS demonstrate 338.1406Da.Calculated value 338.139234Da, deviation 4ppm.
Outward-and 7-[(1S, 3S, 5R)-(8-aza-bicyclo [3.2.1] oct-3-yl) oxygen base]-3-benzene
And furans-2-base-chromen-2-one hydrochloride
According to method A from outside-7-[(1S, 3S, 5R)-(8-tert-butoxycarbonyl-8-aza-bicyclo [3.2.1] oct-3-yl) oxygen base]-preparation of 3-bromo-chromen-2-one and 2-cumarone boric acid.[M+H]+LC-ESI-HRMS demonstrate 388.1554Da.Calculated value 388.154884Da, deviation 1.3ppm.
EXPERIMENTAL EXAMPLE
The vitro inhibition activity
As described in WO 97/16451, tested monoamine neurotransmitter dopamine (DA) in the inhibition synaptosome of chemical compound lot, the ability of the re-uptake of norepinephrine (NA) and serotonin (5-HT).
Experimental value is given IC
50(will
3H-DA,
3H-NA, or
3The specificity of H-5-HT is in conjunction with the concentration (μ M) of the experiment material of inhibition 50%).
As seen the experimental result that the The compounds of this invention of selecting by test from following table obtains:
Table 1
| Experimental compound | 5-HT-absorbs IC 50(μM) | DA-absorbs IC 50(μM) | NA-absorbs IC 50(μM) |
| First kind of compound of method A: outer-7-[(1S, 3S, 5R)-(8-aza-bicyclo [3.2.1]-oct-3-yl) oxygen base]-3-furans-2-base-chromen-2-one | 0.0077 | 0.034 | 0.0043 |
| Second kind of compound of method A: outer-7-[(1S, 3S, 5R)-(8-aza-bicyclo [3.2.1]-oct-3-yl) oxygen base]-3-furans-3-base-chromen-2-one | 0.010 | 0.0099 | 0.00048 |
| The third compound of method A: outer-7-[(1S, 3S, 5R)-(8-aza-bicyclo [3.2.1]-oct-3-yl) oxygen base]-3-cumarone-2-base-chromen-2-one | 0.0091 | 0.70 | 0.84 |
Claims (9)
1. the compound of formula I:
Any mixture of its any stereoisomer or its steric isomer,
Or its pharmacy acceptable salt,
Wherein
Q represents chromene-2-ketone group;
This chromen-2-one base is replaced by furyl or benzofuryl;
R
1Represent hydrogen.
2. the compound of claim 1, wherein
The Q representative is by the chromen-2-one-7-base of furyl or benzofuryl replacement.
3. the compound of claim 1, it is
Outward-and 7-[(1S, 3S, 5R)-(8-aza-bicyclo [3.2.1] oct-3-yl) oxygen base]-3-furans-2-base-chromen-2-one;
Outward-and 7-[(1S, 3S, 5R)-(8-aza-bicyclo [3.2.1] oct-3-yl) oxygen base]-3-furans-3-base-chromen-2-one;
Outward-and 7-[(1S, 3S, 5R)-(8-aza-bicyclo [3.2.1] oct-3-yl) oxygen base]-3-cumarone-2-base-chromen-2-one;
Or its pharmacy acceptable salt.
4. pharmaceutical composition, it comprises among the claim 1-3 that treats significant quantity each compound, any mixture of its any stereoisomer or its steric isomer, or its pharmacy acceptable salt, and at least a pharmaceutically acceptable carrier, vehicle or thinner.
5. any mixture of each compound, its any stereoisomer or its steric isomer or its pharmacy acceptable salt are used to prepare the purposes of medicine among the claim 1-3.
6. the purposes of claim 5 is used for the preparation treatment, prevents or alleviates Mammals, comprises the pharmaceutical composition of Human diseases or obstacle or illness, and described disease, obstacle or illness are replied the inhibition of monoamine neurotransmitter re-uptake in the central nervous system.
7. the purposes of claim 6, wherein said disease, obstacle or illness are affective disorder, depressed, pseudodementia, Ganser's syndrome, obsessional idea and behavior disorder, Phobias, memory impairment, the loss of memory, the distractibility hyperkinetic syndrome, fat, anxiety, eating disorder, Parkinson's disease, Parkinson, dull-witted, specific phobia disease, social phobia, social anxiety disorder, nervous obstacle after the wound, acute stress disorder, the chronic stress obstacle, drug habit, drug abuse, the drug abuse tendency, cocaine abuse, the nicotine abuse, tobacco abuse, alcohol addiction, alcoholism, the kleptomania, stop the Withrawal symptom that the use addictive substance causes, pain, chronic pain, inflammatory pain, neuropathic pain, diabetes nerve pain, migraine, tension-type headache, chronic tension-type headache, the pain relevant with depression, fibromyalgia, sacroiliitis, osteoarthritis, rheumatoid arthritis, back pain, pain caused by cancer, intestines easily swash property pain, irritable bowel syndrome, post-operative pain, mastectomy postoperative pain syndrome (PMPS), pain after the apoplexy, drug-induced neuropathy, diabetic neuropathy, sympathetic nerve maintenance pain, trigeminal neuralgia, toothache, muscular fascia pain, phantom limb pain, exessive appetite, premenstrual syndrome, premenstrual dysphoric disorder, the evening luteal phase syndrome, posttraumatic syndrome, chronic fatigue syndrome, the persistence persistent vegetative state, the urinary incontinence, the pressure incontinence, urge incontinence, the incontinence at night, sexual dysfunction, premature ejaculation, it is difficult to erect, erective dysfunction, too early female orgasm, restless legs syndrome, Periodic limb movement disorder, eating disorder, anorexia nervosa, somnopathy, PDD, autism, the A Sibogeer obstacle, the special obstacle of thunder, childhood disintegrative disorder, the learning capacity forfeiture, motor skill disorder, mutism, trichotillomania, narcolepsy, the apoplexy retarded depression, apoplexy inductive brain injury, apoplexy inductive neuronal damage, Ji Ledelatulei syndrome, tinnitus, tic disorder, body deformability mental disorder, disabled after oppositional defiant disorder or the apoplexy.
8. the purposes of claim 6, wherein said disease, obstacle or illness are the atypia depression, be secondary to the depression of pain, major depressive disorder, dysthymic disorder, bipolar disorder, I type bipolar disorder, II type bipolar disorder, cyclothymic disorder, the affective disorder that causes by the general medicine illness, material inductive affective disorder, the Phobias of no agoraphobia, the Phobias that agoraphobia is arranged, the agoraphobia of no Phobias medical history, panic attack, generalized-anxiety disorder, old and feeble dementia, senile dementia, Alzheimer, mongolism, the dull-witted complex of acquired immune deficiency syndrome (AIDS), aging memory machine dysfunction.
9. any mixture of each compound, its any stereoisomer or its steric isomer or its pharmacy acceptable salt among the claim 1-3 are used as medicine.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87580606P | 2006-12-20 | 2006-12-20 | |
| DKPA200601678 | 2006-12-20 | ||
| DKPA200601678 | 2006-12-20 | ||
| US60/875,806 | 2006-12-20 | ||
| PCT/EP2007/064130 WO2008074797A1 (en) | 2006-12-20 | 2007-12-18 | Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101563344A CN101563344A (en) | 2009-10-21 |
| CN101563344B true CN101563344B (en) | 2011-11-16 |
Family
ID=40639626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007800472000A Expired - Fee Related CN101563344B (en) | 2006-12-20 | 2007-12-18 | Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
Country Status (12)
| Country | Link |
|---|---|
| KR (1) | KR20090089439A (en) |
| CN (1) | CN101563344B (en) |
| AR (1) | AR064457A1 (en) |
| AT (1) | ATE486868T1 (en) |
| BR (1) | BRPI0719578A2 (en) |
| DE (1) | DE602007010356D1 (en) |
| DK (1) | DK2121677T3 (en) |
| NZ (1) | NZ577071A (en) |
| PT (1) | PT2121677E (en) |
| RU (1) | RU2009119919A (en) |
| TW (1) | TW200836732A (en) |
| ZA (1) | ZA200903278B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023528547A (en) | 2020-05-29 | 2023-07-04 | テグ－キョンプク メディカル イノベーション ファウンデーション | A 5-membered heteroaryl derivative containing at least one N, and a pharmaceutical composition for use in preventing or treating a psychiatric disorder containing the same as an active ingredient |
| EP4159725A4 (en) | 2020-05-29 | 2023-12-20 | Daegu-Gyeongbuk Medical Innovation Foundation | Carboxamide derivative and pharmaceutical composition comprising same as active ingredient for preventing or treating mental illness |
| US20230212121A1 (en) | 2020-05-29 | 2023-07-06 | Daegu-Gyeongbuk Medical Innovation Foundation | Sulfonamide derivative and pharmaceutical composition comprising same as active ingredient for preventing or treating mental illness |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006035034A1 (en) * | 2004-09-30 | 2006-04-06 | Neurosearch A/S | Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
-
2007
- 2007-11-20 TW TW096143836A patent/TW200836732A/en unknown
- 2007-12-18 DE DE602007010356T patent/DE602007010356D1/en active Active
- 2007-12-18 ZA ZA200903278A patent/ZA200903278B/en unknown
- 2007-12-18 RU RU2009119919/04A patent/RU2009119919A/en not_active Application Discontinuation
- 2007-12-18 AT AT07857757T patent/ATE486868T1/en active
- 2007-12-18 KR KR1020097012929A patent/KR20090089439A/en not_active Application Discontinuation
- 2007-12-18 DK DK07857757.4T patent/DK2121677T3/en active
- 2007-12-18 CN CN2007800472000A patent/CN101563344B/en not_active Expired - Fee Related
- 2007-12-18 NZ NZ577071A patent/NZ577071A/en unknown
- 2007-12-18 BR BRPI0719578-8A patent/BRPI0719578A2/en not_active IP Right Cessation
- 2007-12-18 PT PT07857757T patent/PT2121677E/en unknown
- 2007-12-19 AR ARP070105734A patent/AR064457A1/en not_active Application Discontinuation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006035034A1 (en) * | 2004-09-30 | 2006-04-06 | Neurosearch A/S | Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| NZ577071A (en) | 2011-07-29 |
| KR20090089439A (en) | 2009-08-21 |
| RU2009119919A (en) | 2011-01-27 |
| TW200836732A (en) | 2008-09-16 |
| ZA200903278B (en) | 2010-07-28 |
| BRPI0719578A2 (en) | 2013-12-17 |
| PT2121677E (en) | 2011-01-25 |
| AR064457A1 (en) | 2009-04-01 |
| CN101563344A (en) | 2009-10-21 |
| DE602007010356D1 (en) | 2010-12-16 |
| ATE486868T1 (en) | 2010-11-15 |
| DK2121677T3 (en) | 2011-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101426790B (en) | 1, 4-diaza-bicyclo [3.2.2] nonyloxadiazolyl derivatives and their medicinal uses | |
| CN101023081A (en) | Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | |
| CN101405287B (en) | Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | |
| CN100368409C (en) | Novel 8-aza-bicyclo not 3.2.1|octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | |
| CN102076679A (en) | Novel tetramethyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | |
| JP2010513392A (en) | Novel chromen-2-one derivatives and their use as monoamine neurotransmitter reuptake inhibitors | |
| CN101563344B (en) | Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | |
| CN101379063A (en) | 3,9-diazabicyclo[3.3.1]nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | |
| CN101796054A (en) | 1,4-diaza-bicycl0(3.2.2)n0nyl pyrimidinyl derivatives useful as nicotinic acetylcholine- receptor ligands | |
| TW201202233A (en) | Novel compounds | |
| JP2008526923A (en) | Novel 8-substituted 8-aza-bicyclo [3.2.1] octane derivatives and their use as monoamine neurotransmitter reuptake inhibitors | |
| CN101812056A (en) | The piperidine derivative that replaces as the novel alkyl of monoamine neurotransmitter re-uptake | |
| JP2010513391A (en) | Novel chromen-2-one derivatives and their use as monoamine neurotransmitter reuptake inhibitors | |
| CN101563343A (en) | Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | |
| JP2008502650A (en) | Novel 9-aza-bicyclo [3.3.1] nonane derivatives and their use as monoamine neurotransmitter reuptake inhibitors | |
| JP2008502652A (en) | Novel alkyl-substituted piperazine derivatives and their use as inhibitors of monoamine neurotransmitter reuptake | |
| CN102428083A (en) | Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | |
| CN101277954A (en) | 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | |
| CN100427484C (en) | 2-methoxymethyl-3-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1]octane tartrate salts | |
| CN101910132A (en) | Novel piperidine-4-carboxylic acid phenyl-alkyl-amide derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | |
| CN101189232A (en) | 3-aryloxy-8-aza-bicyclo [3.2.1.] oct-6-ene derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | |
| JP2009526023A (en) | 3,9-Diazabicyclo [3.3.1] nonane derivatives and their use as monoamine neurotransmitter reuptake inhibitors | |
| JP2011511030A (en) | Novel phenylethynyl derivatives of 8-aza-bicyclo [3.2.1] octane and their use as monoamine neurotransmitter reuptake inhibitors | |
| CN100372850C (en) | Novel 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | |
| CN100551924C (en) | 8-aza-bicyclo [3.2.1] Octane derivatives and they purposes as monoamine neurotransmitter re-uptake |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20111116 Termination date: 20121218 |